REG - Roquefort Theraptcs. - Lyramid SPA & MK Cell License Update

Roquefort TherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260325:nRSY9825Xa&default-theme=true

RNS Number : 9825X  Roquefort Therapeutics PLC  25 March 2026

25 March 2026

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Lyramid SPA & MK Cell License Update

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company,
announces it has agreed to extend the Longstop Dates (defined below) in
relation to the binding share purchase agreement ("Lyramid SPA") for the sale
of its wholly owned subsidiary Lyramid Pty Ltd to Pleiades Pharma Ltd
("Pleiades"), and the binding agreement in relation to the out-licensing of MK
Cell patents to Pleiades ("MK Cell Out-License") to 31 December 2026.

 

As previously announced, completion of the Lyramid SPA is contingent on
Pleaides completing a fundraising round by a certain date (the "Lyramid SPA
Longstop Date"). The current Lyramid SPA Longstop Date is 31 March 2026.
Similarly, in accordance with the terms of the MK Cell Out-License, Pleaides
is required to complete a fundraising round by a certain date (the "MK Cell
Longstop Date"). The current MK Cell Longstop Date is 2 May 2025.

 

Pleiades' fundraising with institutional and sovereign wealth fund investors
in the GCC (Gulf Cooperation Council) is continuing, however, the current
Lyramid SPA Longstop Date and MK Cell Longstop Date (together the "Longstop
Dates") do not allow sufficient time for Pleiades to complete its fundraising
round and accordingly the parties have agreed to extend the Longstop Dates.
All other terms in the Lyramid SPA and MK Cell Out-License remain unchanged.

 

Regulatory Information

This Announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").

 

-ENDS-

 
Enquiries:
 Roquefort Therapeutics plc                                    +44 (0)20 3918 8633

 Stephen West (Chairman)

 SP Angel Corporate Finance LLP (Joint Broker)                 +44 (0)20 3470 0470

 David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

                                                               +44 (0)20 4530 6926

 Shard Capital Partners LLP (Joint Broker)

 Damon Heath

                                                               +61 (0)8 9223 2222

 CPS Capital Group Pty Ltd (Joint Broker)

 Jason Peterson / David Valentino

 Burson Buchanan (Public Relations)                            +44 (0)20 7466 5000

 Henry Harrison Topham / Jamie Hooper / Toto Berger

 

LEI: ‎254900P4SISIWOR9RH34

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDDGDXXGDDGLS



            Copyright 2019 Regulatory News Service, all rights reserved